Structure-based design of SARS-CoV-2 papain-like protease inhibitors
Copyright © 2023 Elsevier Masson SAS. All rights reserved..
The COVID-19 pandemic is caused by SARS-CoV-2, an RNA virus with high transmissibility and mutation rate. Given the paucity of orally bioavailable antiviral drugs to combat SARS-CoV-2 infection, there is a critical need for additional antivirals with alternative mechanisms of action. Papain-like protease (PLpro) is one of the two SARS-CoV-2 encoded viral cysteine proteases essential for viral replication. PLpro cleaves at three sites of the viral polyproteins. In addition, PLpro antagonizes the host immune response upon viral infection by cleaving ISG15 and ubiquitin from host proteins. Therefore, PLpro is a validated antiviral drug target. In this study, we report the X-ray crystal structures of papain-like protease (PLpro) with two potent inhibitors, Jun9722 and Jun9843. Subsequently, we designed and synthesized several series of analogs to explore the structure-activity relationship, which led to the discovery of PLpro inhibitors with potent enzymatic inhibitory activity and antiviral activity against SARS-CoV-2. Together, the lead compounds are promising drug candidates for further development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:264 |
|---|---|
| Enthalten in: |
European journal of medicinal chemistry - 264(2024) vom: 15. Jan., Seite 116011 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jadhav, Prakash [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral |
|---|
| Anmerkungen: |
Date Completed 01.01.2024 Date Revised 01.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejmech.2023.116011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365558869 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365558869 | ||
| 003 | DE-627 | ||
| 005 | 20240108140843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejmech.2023.116011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1246.xml |
| 035 | |a (DE-627)NLM365558869 | ||
| 035 | |a (NLM)38065031 | ||
| 035 | |a (PII)S0223-5234(23)00978-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jadhav, Prakash |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Structure-based design of SARS-CoV-2 papain-like protease inhibitors |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.01.2024 | ||
| 500 | |a Date Revised 01.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a The COVID-19 pandemic is caused by SARS-CoV-2, an RNA virus with high transmissibility and mutation rate. Given the paucity of orally bioavailable antiviral drugs to combat SARS-CoV-2 infection, there is a critical need for additional antivirals with alternative mechanisms of action. Papain-like protease (PLpro) is one of the two SARS-CoV-2 encoded viral cysteine proteases essential for viral replication. PLpro cleaves at three sites of the viral polyproteins. In addition, PLpro antagonizes the host immune response upon viral infection by cleaving ISG15 and ubiquitin from host proteins. Therefore, PLpro is a validated antiviral drug target. In this study, we report the X-ray crystal structures of papain-like protease (PLpro) with two potent inhibitors, Jun9722 and Jun9843. Subsequently, we designed and synthesized several series of analogs to explore the structure-activity relationship, which led to the discovery of PLpro inhibitors with potent enzymatic inhibitory activity and antiviral activity against SARS-CoV-2. Together, the lead compounds are promising drug candidates for further development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Antiviral | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a PL(pro) | |
| 650 | 4 | |a Papain-like protease | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 7 | |a Papain |2 NLM | |
| 650 | 7 | |a EC 3.4.22.2 |2 NLM | |
| 650 | 7 | |a papain-like protease, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.2 |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Protease Inhibitors |2 NLM | |
| 700 | 1 | |a Huang, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Osipiuk, Jerzy |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaoming |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Haozhou |e verfasserin |4 aut | |
| 700 | 1 | |a Tesar, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Endres, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Jedrzejczak, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Xufang |e verfasserin |4 aut | |
| 700 | 1 | |a Joachimiak, Andrzej |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Jianfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of medicinal chemistry |d 1994 |g 264(2024) vom: 15. Jan., Seite 116011 |w (DE-627)NLM106608835 |x 1768-3254 |7 nnns |
| 773 | 1 | 8 | |g volume:264 |g year:2024 |g day:15 |g month:01 |g pages:116011 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejmech.2023.116011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 264 |j 2024 |b 15 |c 01 |h 116011 | ||